J&J said first-quarter revenues came in at $21.9 billion, up 2.4% on the same period of 2024, which was a little above ...

The EU approval comes after Eisai and Biogen were given approval for a new once-monthly intravenous maintenance dose of ...

AI and digital health have tremendous potential to improve patient outcomes across healthcare, but in rare disease – where small patient groups, delayed diagnosis, and barriers to access create major ...

Recorded onsite at The Eden Project in Cornwall, the conversation centred around the Adelphi Group-sponsored panel, ‘The ...

Theravia made more than €50 million in revenues in 2024 and has seen its sales rise by an annual rate of around 10% in recent ...

Shares in Ironwood Pharma fell by a third after it revealed that the FDA is insisting on a new phase 3 trial of its short ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

By leveraging data, digitalisation, and artificial intelligence (AI), the network aims to transform its operations, making them more efficient and responsive to the challenges and opportunities of the ...

At Reuters Pharma USA last month, editor-in-chief Jonah Comstock caught up with John Androsavich, general manager of Ginkgo Datapoints, an AI-driven CRO launched by Ginkgo Bioworks last September. In ...

For decades, treatment options for rare diseases have been limited, often focusing on symptom management rather than ...

Jazz Pharma has agreed to pay $145 million to settle lawsuits claiming it illegally acted to prevent generic versions of its ...